

Perinatal Depression

Common: 12-15% in pregnancy, 22% postpartum, in 5-10% of non-gestational parents, more common and lower rates of screening and treatment in BIPOC individuals

Screening:

PHQ-2 → PHQ-9/EPDS

Initial prenatal visit

At least once during pregnancy

Postpartum visit

Well child visits through 12 mos postpartum

For positive screens, <u>assess safety</u> (See <u>page 27</u> for additional guidance)

<u>Columbia Suicide Severity Rating Scale (CSSRS)</u> or <u>Ask Suicide Screening Questions (ASQ)</u>

Ask about thoughts about harming baby: "It can be very overwhelming to be a new parent. Sometimes people have upsetting thoughts about hurting their babies, either by accident or on purpose. Have you had thoughts like this?" Refer to emergency services as needed

Differential Diagnosis:

- *Major depressive disorder
- *Persistent depressive disorder
- *Adjustment disorder
- *Depression secondary to medical condition (e.g. hypothyroidism, anemia)/substance use
- *Depression secondary to another psychiatric disorder (e.g. bipolar disorder, PTSD)
- *Consider postpartum psychosis (emergency)

For mild depression:

Education: https://www.nimh.nih.gov/health/publications/perinatal-depression/index.shtml

Closer monitoring (PHQ-9/EPDS)

Exercise, behavioral activation

Social support

Address sleep issues

Rule out medical causes, bipolar disorder

Moderate/severe depression: Add medication and/or psychotherapy; shared decision-making with patient (and partner, as applicable), weighing risks of medications and untreated depression, and considering alternative/non-medication treatments

Risks of untreated depression:

- *Functional impairment, hospitalization, suicide
- *Poor prenatal care/self-care; smoking, substance use
- *Higher rates of miscarriage, preeclampsia, preterm birth
- *Problems with bonding/attachment
- *Longer hospital stays, more NICU admissions for baby
- *Increased rates of psychiatric disorders in children



May need increase in dose later in pregnancy

Risks of antidepressants:

- *Common and serious side effects
- *No consistent increase in rates of malformations
- *Persistent pulmonary hypertension of the newborn (PPHN; 2.9 vs. 1.8/1000)
- *Neonatal adaptation syndrome in 30%; worse if also taking benzodiazepines
- *Monitor breastfed infants for sedation/poor feeding; case reports of seizures with exposure to bupropion during lactation

Alternative/additional treatments:

- *Psychotherapy (CBT, IPT, therapy that has helped in past)
- *Exercise, yoga, bright light, omega-3-fatty-acids (EPA:DHA>1.5)
- *For severe/treatment-resistant depression, consider ECT, TMS, brexanolone, day treatment/inpatient programs

Goal:

Treat to remission Track PHQ-9/EPDS to measure progress/outcome

Perinatal Depression Medications

Drug Name	Starting Dose ^a (mg/day)	Up titration schedule	Use in Pregnancy	Use during Lactation
SSRIs ^b				
Citalopram (Celexa)	10	Increase to 20 mg/day after one week Then, increase by 10-20 mg every 4 weeks ^c (max dose 40 mg/day) ^d	SSRIs not associated with increase in malformations	RIDe < 10%; reports of sedation, fussiness, weight loss in infants; monitor weight gain, behavioral effects
Escitalopram (Lexapro)	5	Increase to 10 mg/day after one week Then, increase to 20 mg/day after 4 weeks ^c (max dose 20 mg/day)	May need dosage increase later in pregnancy	RIDe < 10%; one report of necrotizing enterocolitis; monitor for sedation, irritability
Fluoxetine (Prozac)	10	Increase to 20 mg/day after one week Then, increase by 10-20 mg every 4 weeks ^c (max dose 80 mg/day)	Possible increased risk of persistent pulmonary hypertension of the newborn (PPHN); 2.9/1000 vs. 1.8/	RID ^e may be > 10%; monitor for behavioral effects, adequate weight gain
Paroxetine (Paxil)	10	Increase to 20 mg/day after one week Then, increase dose by 10-20 mg every 4 weeks ^c (max dose 50 mg/day)	1000 baseline; lowest risk with sertraline	RID ^e generally 5% or less; few adverse effects; monitor for behavioral effects (e.g. insomnia, restlessness, increased crying)
Sertraline (Zoloft)	25	Increase to 50 mg/day after one week Then, increase by 25-50 mg every 4 weeks ^c (max dose 200 mg/day)	Transient neonatal adaptation syndrome (NAS) in 30% of exposed infants	Low concentrations in breast milk and infant; RIDe generally 2% or less; few adverse effects in infants; considered preferred antidepressant in breastfeeding
SNRIs ^b				
Duloxetine (Cymbalta)	30	Increase dose to 60 mg/day after one week (max 120 mg/day; rarely need > 60 mg/d)	NAS (see above); possible inc risk of heart defects, miscarriage, postpartum hemorrhage	Few reports; RID ^e < 1%; no adverse effects; monitor for sedation, adequate growth
Venlafaxine (Effexor) XR	37.5	Increase to 75 mg/day after one week Then, increase by 37.5-75 mg every 4 weeks ^c (max dose 225 mg/day)	Increased risk for PPHN, NAS (see above); increased risk of gestational hypertension	RID ^e 3-12%; rare adverse effects reported in infants; monitor baby for excessive sedation, adequate weight gain
OTHER ^b				
Bupropion ^f (Wellbutrin) XL	150	Increase by 300 mg/day XL every 4 weeks ^c (max dose 450 mg/day)	No overall inc in malformations ?inc in LVOT ^g heart defects	RID ^e up to 5.1% 2 reports of seizures in breastfed infants
Mirtazapine ^h (Remeron)	7.5	Increase to 15 mg qhs after one week Then, increase by 15 mg every 4 weeks ^c (max dose 45 mg/day)	No increase in malformations NAS (see above)	Few reports; RID ^e < 2%; no adverse effects noted; monitor for behavioral effects, adequate growth
		Then, increase by 15 mg every 4 weeks ^c (max dose 45 mg/day)		noted; monitor for behavioral effe

^aWith comorbid anxiety disorder, use lower starting dose

^eRID = relative infant dose

 $\ensuremath{^{\text{f}}}\xspace$ do not give if history of bulimia or seizures; seizure risk limits dose

gLVOT = left ventricular outflow tract

4/23/23

PERINATAL PCL: (877) 725-4666

^bAntidepressants are associated with increased suicidal thinking and behavior in young adults; monitor closely for worsening or emerging suicidality

^cas needed to treat continued depressive symptoms

dmaximum dose 40 mg/day due to risk of QT prolongation

hincreases appetite, sedating; may help with hyperemesis, insomnia

Perinatal Depression Resources

Review article:

Mesches GA, Wisner KL, Betcher HK. A common clinical conundrum: antidepressant treatment of depression in pregnant women. Seminars in Perinatology 2020; 44:151229.

PHQ-9 in multiple languages:

https://www.phqscreeners.com

EPDS in multiple languages:

Edinburgh Postnatal Depression Scale (EPDS) (perinatalservicesbc.ca)

Columbia Suicide Severity Rating Scale (CSSRS):

https://cssrs.columbia.edu/documents/c-ssrs-screener-triage-primary-care/

Ask Suicide Screening Questions (ASQ):

https://sprc.org/online-library/asq-ask-suicide-screening-questions-toolkit/

NIMH brochure for patients about perinatal depression (available in English and in Spanish):

https://www.nimh.nih.gov/health/publications/perinatal-depression/index.shtml

Mothers and Babies Program

Information, training, and resources for therapy for perinatal stress and depression based on cognitive behavioral therapy and attachment theory. Website also has information for patients/parents, including how to find a therapist.

http://www.mothersandbabiesprogram.org/

Article about interpersonal therapy (IPT) for postpartum depression:

This is an article for providers that describes interpersonal therapy (IPT) for postpartum depression, its rationale, structure, and content.

Stuart S. Interpersonal psychotherapy for postpartum depression. Clin Psychol Psychother 2012; 19:134-140.

Article about importance of and prescribing sleep for postpartum depression:

Leistikow N, Baller EB, Bradshaw PJ, et al. Prescribing sleep: an overlooked treatment for postpartum depression. Biological Psychiatry 2022, doi.org/10.1016/j.biopsych.2022.03.006